Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Csts Health Care Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners but are concentrated within 1 distinct art unit. This suggests that while the examiners may differ, the technical and procedural standards of the art unit remain constant across the portfolio.
The busiest examiner, BOWLES, DAVID PAUL, is handling 1 pending office action. Because there are 2 pending office actions in total, the workload is split between two different examiners. This distribution across 2 distinct examiners requires the practitioner to manage two different interpersonal dynamics within the same 1 distinct art unit. Each of the 2 pending office actions must be addressed according to the specific feedback of the assigned examiner.
The focus on 1 distinct art unit for both 2 pending office actions allows for a unified approach to the technical subject matter. Practitioners should monitor how the 2 distinct examiners interpret the same art unit's guidelines and prior art. Successfully addressing the 1 action with BOWLES, DAVID PAUL is essential for the overall progress of the 2 pending office actions. This structure allows for some consistency in the legal arguments used across the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOWLES, DAVID PAUL | 1 | 72.7% | +22.4% |
| ROSSI, VY BUI | 1 | 29.5% | +36.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18356688 | PLATELET ALPHA-GRANULES FOR DELIVERY OF MULTIPLE PROTEINS | BOWLES, DAVID PAUL | 30d |
| 18071590 | THERMODYNAMIC MEASURES ON PROTEIN-PROTEIN INTERACTION NETWORKS FOR CANCER THERAPY | ROSSI, VY BUI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18356688 | PLATELET ALPHA-GRANULES FOR DELIVERY OF MULTIPLE PROTEINS | BOWLES, DAVID PAUL | 30d |
| 18071590 | THERMODYNAMIC MEASURES ON PROTEIN-PROTEIN INTERACTION NETWORKS FOR CANCER THERAPY | ROSSI, VY BUI | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18356688 | PLATELET ALPHA-GRANULES FOR DELIVERY OF MULTIPLE PROTEINS | BOWLES, DAVID PAUL | 1654 | §103§112 | Non-Final OA | 30d | Pending | Jul 21, 2023 |
| 18071590 | THERMODYNAMIC MEASURES ON PROTEIN-PROTEIN INTERACTION NETWORKS FOR CANCER THERAPY | ROSSI, VY BUI | — | §101§103§112DP | Non-Final OA | — | Pending | Nov 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial